NVS [NYSE]
Novartis AG
Index- P/E8.26 EPS (ttm)10.73 Insider Own9.30% Shs Outstand2.23B Perf Week3.83%
Market Cap215.45B Forward P/E12.99 EPS next Y6.82 Insider Trans0.00% Shs Float2.15B Perf Month-2.84%
Income24.18B PEG1.77 EPS next Q1.53 Inst Own9.60% Short Float0.30% Perf Quarter2.30%
Sales53.00B P/S4.07 EPS this Y202.30% Inst Trans-0.49% Short Ratio2.47 Perf Half Y8.24%
Book/sh27.66 P/B3.20 EPS next Y9.17% ROA19.30% Target Price104.40 Perf Year0.81%
Cash/sh7.74 P/C11.45 EPS next 5Y4.67% ROE40.30% 52W Range79.09 - 95.17 Perf YTD1.35%
Dividend3.33 P/FCF37.83 EPS past 5Y30.60% ROI9.70% 52W High-6.85% Beta0.53
Dividend %3.75% Quick Ratio1.00 Sales past 5Y1.40% Gross Margin71.00% 52W Low12.09% ATR1.39
Employees110000 Current Ratio1.20 Sales Q/Q0.90% Oper. Margin22.90% RSI (14)54.55 Volatility1.16% 1.50%
OptionableYes Debt/Eq0.51 EPS Q/Q9.30% Profit Margin45.60% Rel Volume1.49 Prev Close88.65
ShortableYes LT Debt/Eq0.40 EarningsApr 26 BMO Payout29.60% Avg Volume2.58M Price88.65
Recom2.00 SMA201.50% SMA500.85% SMA2002.73% Volume0 Change0.00%
May-09-22Downgrade Wolfe Research Outperform → Peer Perform
Jan-10-22Resumed Citigroup Buy
Dec-14-21Downgrade Redburn Buy → Neutral
Dec-06-21Downgrade Exane BNP Paribas Outperform → Neutral
Dec-03-21Downgrade Bryan Garnier Buy → Neutral
Sep-20-21Downgrade Deutsche Bank Hold → Sell
Mar-22-21Initiated Bernstein Mkt Perform
Mar-10-21Downgrade Argus Buy → Hold
Feb-01-21Downgrade Cowen Outperform → Market Perform $110 → $105
Jan-15-21Initiated Deutsche Bank Buy
Sep-29-20Initiated Berenberg Buy
Sep-10-20Upgrade UBS Neutral → Buy
Sep-01-20Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-15-20Upgrade Citigroup Neutral → Buy
Mar-10-20Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20Downgrade Guggenheim Buy → Neutral
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
May-20-22 08:34AM  
02:00AM  
May-19-22 12:34PM  
May-18-22 10:37AM  
May-17-22 05:59PM  
May-13-22 07:15AM  
May-12-22 04:04PM  
10:28AM  
May-11-22 11:15AM  
May-06-22 11:02AM  
May-05-22 01:37PM  
12:30PM  
11:45AM  
May-04-22 03:00AM  
May-03-22 11:53AM  
07:00AM  
May-02-22 10:45AM  
Apr-29-22 12:33PM  
10:32AM  
Apr-27-22 12:17PM  
09:48AM  
09:45AM  
06:00AM  
05:59AM  
Apr-26-22 05:30PM  
04:08PM  
10:15AM  
06:49AM  
04:36AM  
03:15AM  
01:24AM  
01:00AM  
Apr-25-22 01:16PM  
Apr-22-22 12:00PM  
09:27AM  
Apr-20-22 10:19AM  
Apr-18-22 06:04AM  
Apr-14-22 01:15AM  
Apr-13-22 10:25AM  
09:09AM  
Apr-12-22 10:23AM  
03:18AM  
Apr-08-22 09:28AM  
Apr-07-22 02:55PM  
12:05PM  
10:06AM  
08:53AM  
Apr-06-22 11:58AM  
09:28AM  
01:15AM  
Apr-05-22 08:29PM  
03:06PM  
01:15AM  
Apr-04-22 11:00AM  
10:36AM  
05:27AM  
01:19AM  
01:00AM  
Apr-02-22 06:43PM  
Apr-01-22 09:09AM  
08:48AM  
Mar-29-22 11:23AM  
06:56AM  
Mar-28-22 02:06PM  
01:27PM  
Mar-25-22 01:43PM  
08:09AM  
08:03AM  
06:35AM  
Mar-24-22 01:39PM  
10:14AM  
08:54AM  
Mar-23-22 05:15PM  
04:19PM  
04:19PM  
Mar-22-22 03:34AM  
Mar-19-22 06:05AM  
Mar-18-22 09:10AM  
Mar-17-22 10:45AM  
Mar-16-22 10:23PM  
12:16PM  
Mar-15-22 11:37AM  
11:07AM  
Mar-14-22 12:57PM  
12:18PM  
06:05AM  
02:15AM  
Mar-13-22 07:00PM  
Mar-10-22 12:27PM  
Mar-09-22 12:54PM  
12:35PM  
Mar-08-22 02:20PM  
08:30AM  
06:27AM  
06:16AM  
Mar-04-22 09:19AM  
Feb-23-22 12:02PM  
Feb-22-22 12:54PM  
Feb-18-22 07:11AM  
01:15AM  
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.